{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T02:24:56Z","timestamp":1770431096680,"version":"3.49.0"},"reference-count":66,"publisher":"Oxford University Press (OUP)","issue":"S1","license":[{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Learning Objectives<\/jats:title><jats:p>After taking all of the CME courses in this supplement the reader will be able to:<\/jats:p><jats:p>Describe the basic biology of various leukemias, multiple myeloma, and myelodysplastic syndrome (MDS). Discuss new targeted treatment strategies for hematologic malignancies. Understand the rationale for the use of nontraditional cytotoxic agents such as arsenic trioxide in the treatment of hematologic malignancies. Examine the role of arsenic trioxide and other novel agents in early-versus accelerated-stage hematologic disease. Discuss the preclinical and clinical efficacy of arsenic trioxide and various agents in treating acute promyelocytic leukemia, MDS, and multiple myeloma.<\/jats:p><jats:p>Access CME test online and receive one hour category 1 credit at CME.TheOncologist.com<\/jats:p><jats:p>Multiple myeloma remains an incurable disease, with median survival rates of 4-6 years even with aggressive, high-dose chemotherapy, bone marrow transplantation, and intensive supportive care. Additionally, multiple myeloma is primarily a disease of the elderly, many of whom cannot tolerate aggressive chemotherapy. Thus, newer treatments with good safety profiles are needed to improve the quality of responses and, hopefully, to translate into prolonged progression and overall survival. The pathophysiology of multiple myeloma is complex, involving many pathways and interactions among cytokines, adhesion molecules, angiogenesis, and mechanisms of resistance, which, taken together, provide multiple targets for novel therapeutic modalities. Agents currently under investigation for treating multiple myeloma include thalidomide and its successors, PS-341, and arsenic trioxide. Thalidomide and immunomodulatory drugs both exhibit activity against multiple myeloma by affecting different levels of the immune system. PS-341 is a proteasome inhibitor that halts the cell cycle, resulting in apoptosis; it also inhibits a key transcription factor and may have antiangiogenic activity. Arsenic trioxide activates multicellular mechanisms to induce apoptosis, inhibit angiogenesis, and stimulate immune responses. Preclinical and early clinical data suggest that combination regimens should be pursued, given the different mechanisms of action of these compounds on the immune system and their non-overlapping toxicities at low dosages.<\/jats:p><\/jats:sec>","DOI":"10.1634\/theoncologist.7-suppl_1-20","type":"journal-article","created":{"date-parts":[[2004,8,25]],"date-time":"2004-08-25T16:25:30Z","timestamp":1093451130000},"page":"20-29","source":"Crossref","is-referenced-by-count":17,"title":["Nontraditional Cytotoxic Therapies for Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1093","volume":"7","author":[{"given":"Mohamad A.","family":"Hussein","sequence":"first","affiliation":[{"name":"Cleveland Clinic Myeloma Research Program, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2002,4,1]]},"reference":[{"key":"2021122216415208300_R1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3322\/canjclin.51.1.15","article-title":"Cancer statistics, 2001","volume":"51","author":"Greenlee","year":"2001","journal-title":"CA Cancer J Clin"},{"key":"2021122216415208300_R2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1053\/ctrv.2000.0188","article-title":"A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma","volume":"26","author":"Rajkumar","year":"2000","journal-title":"Cancer Treat Rev"},{"key":"2021122216415208300_R3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0889-8588(05)70419-6","article-title":"Standard therapy versus autologous transplantation in multiple myeloma","volume":"11","author":"Attal","year":"1997","journal-title":"Hematol Oncol Clin North Am"},{"key":"2021122216415208300_R4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V91.1.3","article-title":"Multiple myeloma: increasing evidence for a multistep transformation process","volume":"91","author":"Hallek","year":"1998","journal-title":"Blood"},{"key":"2021122216415208300_R5","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s004320050011","article-title":"The biology of multiple myeloma","volume":"126","author":"Drach","year":"2000","journal-title":"J Cancer Res Clin Oncol"},{"key":"2021122216415208300_R6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(00)00019-2","article-title":"New insights into role of microenvironment in multiple myeloma","volume":"355","author":"Tricot","year":"2000","journal-title":"Lancet"},{"key":"2021122216415208300_R7","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood.V97.2.346","article-title":"Chemokine stromal cell-derived factor-1\u03b1 modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1\/fibronectin and VCAM-1","volume":"97","author":"Sanz-Rodriguez","year":"2001","journal-title":"Blood"},{"key":"2021122216415208300_R8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"issue":"suppl 3","key":"2021122216415208300_R9","first-page":"14","article-title":"Role of cytokines in multiple myeloma","volume":"36","author":"Anderson","year":"1999","journal-title":"Semin Hematol"},{"key":"2021122216415208300_R10","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.V87.3.1104.bloodjournal8731104","article-title":"Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B","volume":"87","author":"Chauhan","year":"1996","journal-title":"Blood"},{"key":"2021122216415208300_R11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1006321828515","article-title":"Proteasome inhibition: a new strategy in cancer treatment","volume":"18","author":"Adams","year":"2000","journal-title":"Invest New Drugs"},{"key":"2021122216415208300_R12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1074-7613(00)80011-4","article-title":"Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells","volume":"10","author":"Catlett-Falcone","year":"1999","journal-title":"Immunity"},{"key":"2021122216415208300_R13","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V87.5.1928.1928","article-title":"Transforming growth factor-\u03b21: differential effects on multiple myeloma versus normal B cells","volume":"87","author":"Urashima","year":"1996","journal-title":"Blood"},{"key":"2021122216415208300_R14","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s004320100250","article-title":"GM-CSF safety and effects in the management of advanced\/refractory multiple myeloma patients: a phase I trial","volume":"127","author":"Hussein","year":"2001","journal-title":"J Cancer Res Clin Oncol"},{"key":"2021122216415208300_R15","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0889-8588(05)70116-7","article-title":"The role of adhesion receptors in the pathogenesis of multiple myeloma","volume":"13","author":"Witzig","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"key":"2021122216415208300_R16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/376517a0","article-title":"Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1","volume":"376","author":"Koch","year":"1995","journal-title":"Nature"},{"key":"2021122216415208300_R17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2141.1994.tb08304.x","article-title":"Bone marrow angiogenesis and progression in multiple myeloma","volume":"87","author":"Vacca","year":"1994","journal-title":"Br J Haematol"},{"key":"2021122216415208300_R18","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood.V93.9.3064.409k07_3064_3073","article-title":"Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma","volume":"93","author":"Vacca","year":"1999","journal-title":"Blood"},{"key":"2021122216415208300_R19","first-page":"728","article-title":"Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies","volume":"59","author":"Bellamy","year":"1999","journal-title":"Cancer Res"},{"key":"2021122216415208300_R20","first-page":"203","article-title":"Regulation of angiogenesis via vascular endothelial growth factor receptors","volume":"60","author":"Veikkola","year":"2000","journal-title":"Cancer Res"},{"key":"2021122216415208300_R21","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood.V95.8.2630","article-title":"Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma","volume":"95","author":"Dankbar","year":"2000","journal-title":"Blood"},{"key":"2021122216415208300_R22","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1182\/blood.V98.2.428","article-title":"Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration","volume":"98","author":"Podar","year":"2001","journal-title":"Blood"},{"key":"2021122216415208300_R23","first-page":"256","article-title":"BCL-X expression in multiple myeloma: possible indicator of chemoresistance","volume":"58","author":"Tu","year":"1998","journal-title":"Cancer Res"},{"key":"2021122216415208300_R24","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood.V85.2.436.436","article-title":"In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain [published erratum appears in Blood 1995;85:3365]","volume":"85","author":"Bergsagel","year":"1995","journal-title":"Blood"},{"key":"2021122216415208300_R25","first-page":"2344","volume-title":"Cancer: Principles & Practice of Oncology","author":"Salmon","year":"1997"},{"key":"2021122216415208300_R26","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/sj.bmt.1701182","article-title":"Long-term follow-up after high-dose therapy for high-risk multiple myeloma","volume":"21","author":"Barlogie","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"2021122216415208300_R27","first-page":"815a","article-title":"High-dose therapy autotransplantation\/intensification vs continued conventional chemotherapy in multiple myeloma patients responding to initial treatment chemotherapy. Results of a prospective randomized trial from the Spanish cooperative group PETHEMA","volume":"98","author":"Blade","year":"2001","journal-title":"Blood"},{"key":"2021122216415208300_R28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/00003495-200060020-00003","article-title":"Potential novel uses of thalidomide: focus on palliative care","volume":"60","author":"Peuckmann","year":"2000","journal-title":"Drugs"},{"key":"2021122216415208300_R29","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide selectivity inhibits tumor necrosis factor alpha production by stimulated human monocytes","volume":"173","author":"Sampaio","year":"1991","journal-title":"J Exp Med"},{"key":"2021122216415208300_R30","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","article-title":"Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation","volume":"177","author":"Moreira","year":"1993","journal-title":"J Exp Med"},{"key":"2021122216415208300_R31","doi-asserted-by":"crossref","first-page":"897","DOI":"10.4065\/75.9.897","article-title":"Thalidomide in the treatment of relapsed multiple myeloma","volume":"75","author":"Rajkumar","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"2021122216415208300_R32","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"2021122216415208300_R33","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2141.2000.01835.x","article-title":"Therapy with thalidomide in refractory multiple myeloma patients\u2014the revival of an old drug","volume":"108","author":"Kneller","year":"2000","journal-title":"Br J Haematol"},{"key":"2021122216415208300_R34","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0037-1963(01)90017-4","article-title":"Thalidomide in the management of multiple myeloma","volume":"38","author":"Barlogie","year":"2001","journal-title":"Semin Hematol"},{"key":"2021122216415208300_R35","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1023\/A:1011132808904","article-title":"Thalidomide and dexamethasone combination for refractory multiple myeloma","volume":"12","author":"Dimopoulos","year":"2001","journal-title":"Ann Oncol"},{"key":"2021122216415208300_R36","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-\u03b1","volume":"163","author":"Corral","year":"1999","journal-title":"J Immunol"},{"key":"2021122216415208300_R37","first-page":"775a","article-title":"Apoptotic signaling induced by immunomodulatory thalidomide analogs (Imids) in human multiple myeloma cells: therapeutic implications","volume":"98","author":"Mitsiades","year":"2001","journal-title":"Blood"},{"key":"2021122216415208300_R38","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood"},{"key":"2021122216415208300_R39","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"2021122216415208300_R40","first-page":"908","article-title":"Molecular therapy for multiple myeloma","volume":"86","author":"Martinelli","year":"2001","journal-title":"Haematologica"},{"key":"2021122216415208300_R41","first-page":"2638","article-title":"The proteasome inhibitor PS-341 in cancer therapy","volume":"5","author":"Teicher","year":"1999","journal-title":"Clin Cancer Res"},{"key":"2021122216415208300_R42","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"key":"2021122216415208300_R43","volume-title":"Clinical development of PS-341: from mice to man. 2000.","author":"Elliot"},{"key":"2021122216415208300_R44","first-page":"516a","article-title":"PS-341 is active in multiple myeloma: preliminary report of a phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies","volume":"96","author":"Stinchcombe","year":"2000","journal-title":"Blood"},{"key":"2021122216415208300_R45","first-page":"774a","article-title":"Phase II study of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy","volume":"98","author":"Richardson","year":"2001","journal-title":"Blood"},{"key":"2021122216415208300_R46","first-page":"495","article-title":"Arsenicals in hematologic cancers","volume":"27","author":"Novick","year":"2000","journal-title":"Semin Oncol"},{"key":"2021122216415208300_R47","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJM199811053391901","article-title":"Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide","volume":"339","author":"Soignet","year":"1998","journal-title":"N Engl J Med"},{"key":"2021122216415208300_R48","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1200\/JCO.2001.19.18.3852","article-title":"United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia","volume":"19","author":"Soignet","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122216415208300_R49","first-page":"1041","article-title":"Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients","volume":"59","author":"Rousselot","year":"1999","journal-title":"Cancer Res"},{"key":"2021122216415208300_R50","first-page":"3065","article-title":"Arsenic trioxide-mediated growth inhibition in MC\/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis","volume":"60","author":"Park","year":"2000","journal-title":"Cancer Res"},{"key":"2021122216415208300_R51","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0145-2126(00)00144-2","article-title":"Co-biomodulation with arsenic trioxide in multiple myeloma","volume":"25","author":"Gallagher","year":"2001","journal-title":"Leuk Res"},{"key":"2021122216415208300_R52","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/blood.V96.4.1525","article-title":"Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis","volume":"96","author":"Roboz","year":"2000","journal-title":"Blood"},{"key":"2021122216415208300_R53","first-page":"6033","article-title":"Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown","volume":"59","author":"Lew","year":"1999","journal-title":"Cancer Res"},{"issue":"suppl 1, pt 1","key":"2021122216415208300_R54","first-page":"638a","article-title":"Pharmacologic concentrations of arsenic trioxide induces growth inhibition and apoptosis in malignant lymphocytes and multiple myeloma cells","volume":"92","author":"Chen","year":"1998","journal-title":"Blood"},{"issue":"suppl 1, pt 1","key":"2021122216415208300_R55","first-page":"638a","article-title":"Arsenic compounds induce apoptosis in multiple myeloma (MM), activate pro-caspase-3 but do not affect BCL2 family members","volume":"92","author":"Tang","year":"1998","journal-title":"Blood"},{"issue":"suppl 2","key":"2021122216415208300_R56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1634\/theoncologist.6-suppl_2-17","article-title":"Arsenic trioxide: an emerging therapy for multiple myeloma","volume":"6","author":"Munshi","year":"2001","journal-title":"The Oncologist"},{"key":"2021122216415208300_R57","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0145-2126(00)00105-3","article-title":"Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As2O3) on myeloma cells","volume":"25","author":"Deaglio","year":"2001","journal-title":"Leuk Res"},{"key":"2021122216415208300_R58","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/sj.onc.1201253","article-title":"Dexamethasone induces apoptosis of multiple myeloma cells in a JNK\/SAP kinase independent mechanism","volume":"15","author":"Chauhan","year":"1997","journal-title":"Oncogene"},{"key":"2021122216415208300_R59","first-page":"786a","article-title":"Glutathione depletion restores arsenic-sensitivity to As2O3-resistant APL cells","volume":"42","author":"Davison","year":"2001","journal-title":"Proc Am Assoc Cancer Res"},{"key":"2021122216415208300_R60","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1182\/blood.V98.3.805","article-title":"Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells","volume":"98","author":"Grad","year":"2001","journal-title":"Blood"},{"issue":"suppl 11, pt 1 of 2","key":"2021122216415208300_R61","first-page":"758a","article-title":"Enhanced cytotoxicity to arsenic trioxide in resistant multiple myeloma by butathione sulfoxime (BSO)","volume":"96","author":"Gartenhaus","year":"2000","journal-title":"Blood"},{"key":"2021122216415208300_R62","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1182\/blood.V93.1.268","article-title":"Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system","volume":"93","author":"Dai","year":"1999","journal-title":"Blood"},{"key":"2021122216415208300_R63","article-title":"Role of glutathione depletion in arsenic-based treatment","volume-title":"VIIIth International Myeloma Workshop of the Multiple Myeloma Research Foundation, Banff, Alberta, Canada, May 4\u20138, 2001.","author":"Boise"},{"issue":"suppl 10, pt 2","key":"2021122216415208300_R64","first-page":"123a","article-title":"Marked antitumor effect of arsenic trioxide (As2O3) in high risk refractory multiple myeloma","volume":"94","author":"Munshi","year":"1999","journal-title":"Blood"},{"key":"2021122216415208300_R65","first-page":"378a","article-title":"A phase II clinical study of arsenic trioxide (ATO) in patients (Pts) with relapsed or refractory multiple myeloma (MM); a preliminary report","volume":"98","author":"Hussein","year":"2001","journal-title":"Blood"},{"key":"2021122216415208300_R66","first-page":"375a","article-title":"Phase I results from a phase I\/II study of arsenic trioxide (As2O3) and ascorbic acid (AA) in relapsed and chemorefractory multiple myeloma","volume":"98","author":"Bahlis","year":"2001","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.7-suppl_1-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.7-suppl_1-20","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/7\/S1\/20\/41838890\/oncolo_7_s1_20.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/7\/S1\/20\/41838890\/oncolo_7_s1_20.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T06:53:19Z","timestamp":1682751199000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/7\/S1\/20\/6387772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4,1]]},"references-count":66,"journal-issue":{"issue":"S1","published-online":{"date-parts":[[2002,4,1]]},"published-print":{"date-parts":[[2002,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.7-suppl_1-20","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2002,4,1]]},"published":{"date-parts":[[2002,4,1]]}}}